(Q37754557)

22 August 2017

title

Novel approaches to therapy for systemic lupus erythematosus: update 2005. (English)

1 reference

systemic lupus erythematosus

22 August 2017

main subject

0 references

3

Yehuda Shoenfeld

1 reference

22 August 2017

Gisele Zandman-Goddard

series ordinal

1

object named as

Gisele Zandman-Goddard

1 reference

22 August 2017

2

Hedi Orbach

1 reference

22 August 2017

publication date

1 July 2005

1 reference

Expert Review of Clinical Immunology

22 August 2017

published in

1 reference

22 August 2017

volume

1

1 reference

22 August 2017

issue

2

1 reference

22 August 2017

page(s)

223-238

1 reference

Novel approaches to therapy for systemic lupus erythematosus

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

Novel Approaches to Therapy for SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: A study of one hundred thirty‐three cases compared with a control group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

Update on therapy--thalidomide in the treatment of lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

Thalidomide in cutaneous lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

Management of lupus erythematosus: recent insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

Methotrexate in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

Central nervous system lupus: a clinical approach to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

Systemic lupus erythematosus. Disease outcome in patients with a disease duration of at least 10 years: second evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

The effect of dehydroepiandrosterone on lumbar spine bone mineral density in patients with quiescent systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

Dehydroepiandrosterone suppresses interleukin 10 synthesis in women with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

Cyclophosphamide in lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

Lipid peroxidation contributes to hydrogen peroxide induced cytotoxicity in renal epithelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

Neuropsychiatric lupus favourable response to low dose i.v. cyclophosphamide and prednisolone (pilot study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

Pattern of neuropsychiatric manifestations and outcome in juvenile systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

A psychiatric perspective on the therapy of psychosis in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

Azathioprine therapy for patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

Mycophenolate mofetil in lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

Mycophenolate mofetil in animal models of autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

Mycophenolate mofetil combined with prednisone for diffuse proliferative lupus nephritis: a histopathological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

Sequential therapies for proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

The safety and efficacy of MMF in lupus nephritis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

Lupus nephritis: treatment with mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

Mycophenolate therapy of SLE membranous nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

Autologous stem cell transplantation for systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

B cell diversity and longevity in systemic autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

An open study of B lymphocyte depletion in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

Novel therapies in lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

Generation and characterization of LymphoStat‐B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

Abetimus sodium: a new therapy for delaying the time to, and reducing the incidence of, renal flare and/or major systemic lupus erythematosus flares in patients with systemic lupus erythematosus who have a history of renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

Costimulation blockade in the treatment of rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

Intravenous immunoglobulin and the kidney--a two-edged sword

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

Intravenous immunoglobulin treatment of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.2.223

21 January 2018

Identifiers

DOI

10.1586/1744666X.1.2.223

1 reference

22 August 2017

1 reference